top of page

The CEO of Corbus on nectin-4 ADCs, integrin biology, and an alternative to GLPs for weight loss

Yuval Cohen describes why he believe his company's nectin-4 ADC has a next generation design, he covers the idea of integrin inhibition for cancer, and describes the oral weight loss pill Corbus will be advancing to the clinic.





Comments


Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page